<strong>ARVO</strong> 2013 Annual Meeting Abstracts by Scientific Section/Group - <strong>Cornea</strong>Saghizadeh 1 . 1 Regenerative Medicine Institute, Cedars-Sinai MedicalCenter, Los Angeles, CA; 2 Ophthalmology and Cell Biology, StateUniversity of New York, Downstate Medical Center, Brooklyn, NewYork, NY; 3 University of California, Los Angeles, CA.Purpose: Human amniotic membrane (HAM) is a commonsubstratum for culturing limbal cells for future transplantation. Bestresults are obtained when amniotic epithelium is removed fromHAM. Most existing methods require long treatments and leave manycells attached to HAM. The purpose was to develop a reliable methodof HAM denuding with effective and fast removal of amnioticepithelium.Methods: Fresh HAM was mechanically separated from chorion, andcryopreserved in PBS with 10% DMSO. After thawing and washing,HAM was de-epithelialized by different methods: soaking in 0.02%EDTA in PBS at 37°C for 1 hour; EDTA followed by gentle scrapingwith electric toothbrush; EDTA followed by scraping with n-heptanolsoaked cotton tip; 125 μg/ml thermolysin in PBS at 37°C for 9 minfollowed by gentle mechanical scraping. Alternatively, HAM placedin CellCrownTM inserts was rubbed on the epithelial side for 10-30seconds with cotton tip soaked in 0.5 M NaOH and immediatelywashed in PBS. Denuded OCT-embedded HAM was cryosectionedand immunostained for typical components of limbal basementmembrane (BM), including laminin α2, γ1, and γ3 chains, α1/α2 typeIV collagen, perlecan, nidogen-2, and fibronectin. NaOH-denudedHAM was used to culture human telomerase-immortalized cornealepithelial cells, limbal cells from corneoscleral rims, and inducedpluripotent stem cells (iPSC) derived from limbal epithelial cells.Cultured cells were checked for putative stem cell marker expression(ΔNp63α, ABCG2, and keratins 14, 15, 17, and 19) byimmunostaining.Results: Control HAM was positive for all BM markers except forlaminin α2 chain that gave weak and inconsistent staining. HAM decellularizationwith EDTA or EDTA with n-heptanol left out manyadherent epithelial cells; rubbing with toothbrush produced localtears. Thermolysin and NaOH resulted in the best cell removal withcontinuous staining for all BM markers tested. However,thermolysin-treated HAM became fragile and could be easilydamaged during manipulation, which was not seen after NaOHdenuding. <strong>Cornea</strong>l epithelial cell line, limbal cells, and limbalderivediPSC all grew well on NaOH-denuded HAM. Cultured cells,especially limbal cells were positive for putative stem cell markers.Conclusions: HAM de-cellularization with NaOH results in rapidand thorough amniotic cell removal, and ensures excellentpreservation of HAM structure and robust stem cell growth ondenuded HAM.Commercial Relationships: Alexander V. Ljubimov, None; DhruvSareen, None; Loren Ornelas, None; Anais Sahabian, None;David M. Hemmati, None; Chantelle A. Ghiam, None; William J.Brunken, None; Yaron S. Rabinowitz, None; Clive Svendsen,None; Mehrnoosh Saghizadeh, NoneSupport: NIH EY13431, CTSI grant UL 1RR033176, andRegenerative Medicine Institute grants.Program Number: 999 Poster Board Number: B0304Presentation Time: 1:00 PM - 2:45 PMExpansion of Human <strong>Cornea</strong>l Epithelial Stem/Progenitor Cells inFeeder-Free Explant CulturesSophie X. Deng, Martin N. Nakatsu, SHEYLA GONZALEZ, Hua Mei.Ophthalmology, Jules Stein Eye Institute, Los Angeles, CA.Purpose: To present a feeder-free culturing method of humancorneal epithelial stem/progenitor cells in vitro.Methods: Primary limbal epithelial cell (LEC) sheets isolated fromhuman sclerocorneal tissues were trypsinized to produce single LECsand co-cultured with growth arrested 3T3-J2 feeder cells for 14 days.Additionally, the outgrowth of LECs from limbal explant pieces wasalso cultured for 14 days in the presence or absence of 3T3-J2 feeder.The phenotype of the cultured LECs was assessed by their mRNAexpression level of putative stem cell markers and differentiationmarker by qRT-PCR and immunocytochemistry. The percentage ofp63 bright cells in each culture was assessed, and the cellproliferation was evaluated by the Ki67 expression and cell number.Results: We observed no significant difference in cultured LECmorphology among each culturing method. The LEC growth rateincreased over 9-fold in NF explant cultures compared to 3T3-J2explant cultures and the adjusted growth rate between NF culturesand 3T3-J2 single LEC cultures had similar yields (p>0.05). Geneexpression of putative limbal stem cell markers, ABCG2 and ΔNp63were elevated among NF cultures compared to the gold standard andexplants on 3T3-J2. We observed a 7.6-fold and 2.2-fold increase inABCG2 and ΔNp63 expression respectively when comparing NFexplant cultures to the gold standard, while there was only a 4.4-foldand 1.4-fold increase in ABCG2 and ΔNp63 expression respectivelywhen comparing 3T3-J2 explant cultures to the gold standard.However, we did observe an increase in K12 expression in NFexplant cultures when compared to the gold standard (6.2-fold).There was a large increase in Ki67 proliferation (4.0-fold) whencompared to the gold standard. There was no difference in Ki67expression between 3T3-J2 explant cultures and the gold standard.Finally, examination of p63α expression in each condition reviewedno discernable differences in the percentage of p63α bright cellsbetween the gold standard (9.0%) and NF explant cultures (10.0%),but we did see a decrease in the 3T3-J2 explant cultures (6%).Conclusions: 3T3 feeder cells may not be necessary for the growthof stem/progenitor cell population in the primary explant culture. Theexplants themselves may already contain niche factors that arerequired for the viability of corneal stem cells.Commercial Relationships: Sophie X. Deng, None; Martin N.Nakatsu, None; SHEYLA GONZALEZ, None; Hua Mei, NoneSupport: CIRM Grant TR2-01768, NIH Grant EY021797Program Number: 1000 Poster Board Number: B0305Presentation Time: 1:00 PM - 2:45 PMSox9, a determinant of hair follicle stemness, identifies a subset ofmurine basal corneal epithelial cells expressing putative stem cellmarkersRachel Sartaj 1 , Aihong Liu 1 , Elaine Fuchs 2 , Mark Rosenblatt 1 .1 Ophthalmology Department, Weill Cornell Medical College, NewYork, NY; 2 Laboratory of Mammalian Cell Biology andDevelopment, Rockefeller University, New York, NY.Purpose: To localize the expression of Sox9 in the cornea and toidentify genes co-expressed with this determinant of hair folliclestemness.Methods: Antibodies against Sox9 were used to immunostaincorneal sections from wild-type mice, and the nuclear localization ofSox9 determined by wide field and confocal microscopy.Localization of Sox9 within the cornea epithelium was confirmed byimmunostaining for GFP in Sox9-eGFP mice expressing GFP underthe control of the sox9 promoter region. <strong>Cornea</strong>l epithelial cells wereisolated from Sox9-egfp mice via sequential enzymatic treatments,and the cell suspension used for FACS sorting to obtain purifiedpopulation of Sox9-expressing (GFP +) cells and Sox9 nonexpressing(GFP-) cells. RNA was separately isolated from GFP +and GFP - populations and qRT-PCR performed to determine therelative expression of putative corneal epithelial stem cell markersABCG2, p63 and N-cadherin (Cdh2) as well as the differentiationmarkers keratin-12 (Krt12) and involucrin (Ivl).©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the <strong>ARVO</strong> Office at arvo@arvo.org.
<strong>ARVO</strong> 2013 Annual Meeting Abstracts by Scientific Section/Group - <strong>Cornea</strong>Results: In the mouse cornea, Sox9 and GFP proteins were located inthe basal cells of central and limbal cornea epithelium in postnatalday 12 (P12) and adult mice (P70). The expression of Sox9 and GFPproteins are restricted to the basal layer of the corneal epithelium atP12 and increases to 2 layers as the Sox9 progeny divides from thebasal layer to one row above. Quantitative PCR experiments showeda significantly higher relative expression of known corneal epithelialstem cell markers in the Sox9- expressing cells obtained by FACSsorting. We found that there was up regulation of ABCG2 (5 fold),p63 (18 fold), and Cdh2 (3.6 fold), in the sox9 expressing cells. Incontrast, when we analyzed the corneal differentiation markers inthese cells, we found down regulation of Krt12 (5 fold) and Ivl (2.5fold).Conclusions: Sox9 may be a novel marker of corneal epithelial stemcells given its localization to basal corneal epithelial layers an its coexpressionwith other putative stem cell markers. A possible role forSox9 in mediating corneal epithelial stemness could have utility inthe diagnosis and treatment of corneal limbal stem cell deficiency.Commercial Relationships: Rachel Sartaj, None; Aihong Liu,None; Elaine Fuchs, None; Mark Rosenblatt, NoneSupport: Starr Foundation Tri-Institutional Stem Cell Initiative,NYSTEM, Research to Prevent BlindnessProgram Number: 1001 Poster Board Number: B0306Presentation Time: 1:00 PM - 2:45 PMLimbal mesenchymal stromal cells (L-MSC) displayimmunosuppressive properties across donor and speciesboundariesDamien G. Harkin 1, 2 , Laura J. Bray 2, 1 , Celena Heazlewood 3 , KerryAtkinson 3 . 1 School of Biomedical Sciences, Queensland University ofTechnology, Brisbane, QLD, Australia; 2 Queensland Eye Institute,Brisbane, QLD, Australia; 3 Mater Medical Research Institute,Brisbane, QLD, Australia.Purpose: We have evaluated the immunosuppressive properties of L-MSC with the view to using these cells in allogeneic cell therapies forcorneal disorders. We hypothesized that L-MSC cultures wouldsuppress T-cell activation, in a similar way to those established fromhuman bone marrow (BM-MSC).Methods: MSC cultures were established from the limbal stroma ofcadaveric donor eye tissue (up to 1 week postmortem) using eitherconventional serum-supplemented growth medium or a commercialserum-free medium optimized for bone marrow derived MSC(MesenCult-XF system). The MSC phenotype was examined by flowcytometry according to current and emerging markers for humanMSC. Immunosuppressive properties were assessed using a mixedlymphocyte reaction (MLR) assay, whereby the white cell fractionfrom two immunologically incompatible blood donors are culturedtogether in direct contact with growth arrested MSC. T-cell activation(proliferation) was measured by uptake of tritiated thymidine. HumanL-MSC were tested in parallel with human BM-MSC and rabbit L-MSC. Human and rabbit L-MSC were also tested for their ability tostimulate the growth of limbal epithelial (LE) cells in colonyformation assays (for both human as well as rabbit LE cells).Results: L-MSC cultures were >95% negative for CD34, CD45 andHLA-DR and positive for CD73, CD90, CD105 and HLA-ABC.Modest levels (30%) of CD146 expression were observed for L-MSCcultures grown in serum-supplemented growth medium, but not thosegrown in MesenCult-XF. All MSC cultures derived from both humanand rabbit tissue suppressed T-cell activation to varying degreesaccording to culture technique and species (MesenCult-XF >> serumfedcultures, rabbit L-MSC >> human L-MSC). All L-MSCstimulated colony formation by LE cells irrespectively of thecombination of cell species used.Conclusions: L-MSC display immunosuppressive qualities, inaddition to their established non-immunogenic cell surface markerprofile, and stimulate LE cell growth in vitro across speciesboundaries. These results support the potential use of allogeneic oreven xenogeneic L-MSC in the treatment of corneal disorders.Commercial Relationships: Damien G. Harkin, None; Laura J.Bray, None; Celena Heazlewood, None; Kerry Atkinson, OsirisTherapeutics Inc (I), Mesoblast Ptl (C)Support: Supported by NHMRC Project Grant No. 553038Program Number: 1002 Poster Board Number: B0307Presentation Time: 1:00 PM - 2:45 PMEDC/NHS cross-linked amniotic membrane preferentiallypreserves corneal epithelial progenitor cells by activating Wnt/βcatenin signalingDavid H. Ma 1 , Hung-Chi Chen 1 , Jui-Yang Lai 2 , Kevin S. Ma 1 , Lung-Kun Yeh 1 , Unique Yang 3 , Jessica Ma 1 . 1 Ophthalmology, Chang GungMemorial Hospital, Taipei, Taiwan; 2 Institute of Biochemical andBiomedical Engineering, Chang Gung University, Taipei, Taiwan;3 Cell Biology, University of California, Berkeley, Berkeley, CA.Purpose: Previously, we have shown that EDC/NHS cross-linkeddenuded amniotic membrane (CLDAM) is compatible for the growthof human limbo-corneal epithelial (HLE) cells in vitro and in vivo(Biomaterials, 2010, 31: 6647-6658), in this study we furtherinvestigate whether CLDAM preferentially preserves HLE progenitorcells and the underlying mechanism.Methods: HLE cells expanded from explants were cultured on dish(HLE/dish), on denuded AM (HLE/DAM) and on CLDAM(HLE/CLDAM). When near confluency, cell density, BrdU labelretention, and colony formation assay (CFA) were analyzed.Immunoconfocal microscopy, Western blot, and Q-PCR for keratin12, connexin 43, ABCG2, deltaNp63α, β-catenin and TCF-4 wereperformed. Finally, selective GSK3β inhibitors SB216763 orSB415286 were added to HLE/dish cultures to evaluate CFA anddeltaNp63α expression.Results: Compared with HLE/dish or HLE/DAM, HLE cells onCLDAM were more compact in morphology, expressed higher levelof p63, ABCG2, and lower level of connexin 43 and keratin 12. CFAwas highest in HLE/CLDAM, so were the nuclear expression of β-catenin and TCF-4. Addition of GSK3-β inhibitors to HLE/dishcultures not only increased CFE but also the expression of stem cellmarker p63.Conclusions: CLDAM showed tendency to better preserve HLEprogenitor cells in vitro, and Wnt/βcatenin signaling may beinvolved, possibly through the activation of p63.Commercial Relationships: David H. Ma, None; Hung-Chi Chen,None; Jui-Yang Lai, None; Kevin S. Ma, None; Lung-Kun Yeh,None; Unique Yang, None; Jessica Ma, NoneSupport: NSC99-2314-B-182A-027-MY3Program Number: 1003 Poster Board Number: B0308Presentation Time: 1:00 PM - 2:45 PMImmobilized HC-HA Preserves Limbal Niche Cell Phenotype toPrevent Limbal Epithelial Progenitor Cells from DifferentiationBo Han 1, 2 , Yingting Zhu 1 , Suzhen Zhang 1 , Scheffer C. Tseng 1 . 1 TissueTech, Miami, FL; 2 Department of Ophthalmology, Union HospitalHuazhong University of Science and Technology, Wuhan, China.Purpose: We have recently reported the success of isolating limbalniche cells (LNC) that can prevent limbal epithelial progenitor cells(LEPC) from differentiation in a reunion assay in 3-dimentional (3D)Matrigel. Amniotic membrane (AM) alone can help expand residuallimbal stem cells in vitro and in vivo. Because we have successfullyisolated heavy chain-hyaluronan complex (HC-HA) from AM, we©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the <strong>ARVO</strong> Office at arvo@arvo.org.
- Page 2 and 3:
ARVO 2013 Annual Meeting Abstracts
- Page 4 and 5:
ARVO 2013 Annual Meeting Abstracts
- Page 6 and 7:
ARVO 2013 Annual Meeting Abstracts
- Page 8 and 9:
ARVO 2013 Annual Meeting Abstracts
- Page 10:
ARVO 2013 Annual Meeting Abstracts
- Page 13 and 14:
ARVO 2013 Annual Meeting Abstracts
- Page 16 and 17:
ARVO 2013 Annual Meeting Abstracts
- Page 18 and 19:
ARVO 2013 Annual Meeting Abstracts
- Page 20 and 21:
ARVO 2013 Annual Meeting Abstracts
- Page 22 and 23:
ARVO 2013 Annual Meeting Abstracts
- Page 24 and 25:
ARVO 2013 Annual Meeting Abstracts
- Page 26 and 27: ARVO 2013 Annual Meeting Abstracts
- Page 28 and 29: ARVO 2013 Annual Meeting Abstracts
- Page 30 and 31: ARVO 2013 Annual Meeting Abstracts
- Page 32 and 33: ARVO 2013 Annual Meeting Abstracts
- Page 34 and 35: ARVO 2013 Annual Meeting Abstracts
- Page 36 and 37: ARVO 2013 Annual Meeting Abstracts
- Page 38 and 39: ARVO 2013 Annual Meeting Abstracts
- Page 40 and 41: ARVO 2013 Annual Meeting Abstracts
- Page 42 and 43: ARVO 2013 Annual Meeting Abstracts
- Page 44 and 45: ARVO 2013 Annual Meeting Abstracts
- Page 46 and 47: ARVO 2013 Annual Meeting Abstracts
- Page 48 and 49: ARVO 2013 Annual Meeting Abstracts
- Page 50 and 51: ARVO 2013 Annual Meeting Abstracts
- Page 52 and 53: ARVO 2013 Annual Meeting Abstracts
- Page 54 and 55: ARVO 2013 Annual Meeting Abstracts
- Page 56 and 57: ARVO 2013 Annual Meeting Abstracts
- Page 58 and 59: ARVO 2013 Annual Meeting Abstracts
- Page 60 and 61: ARVO 2013 Annual Meeting Abstracts
- Page 62 and 63: ARVO 2013 Annual Meeting Abstracts
- Page 64 and 65: ARVO 2013 Annual Meeting Abstracts
- Page 66 and 67: ARVO 2013 Annual Meeting Abstracts
- Page 68 and 69: ARVO 2013 Annual Meeting Abstracts
- Page 70 and 71: ARVO 2013 Annual Meeting Abstracts
- Page 72 and 73: ARVO 2013 Annual Meeting Abstracts
- Page 74 and 75: ARVO 2013 Annual Meeting Abstracts
- Page 78 and 79: ARVO 2013 Annual Meeting Abstracts
- Page 80 and 81: ARVO 2013 Annual Meeting Abstracts
- Page 82 and 83: ARVO 2013 Annual Meeting Abstracts
- Page 84 and 85: ARVO 2013 Annual Meeting Abstracts
- Page 86 and 87: ARVO 2013 Annual Meeting Abstracts
- Page 88 and 89: ARVO 2013 Annual Meeting Abstracts
- Page 90 and 91: ARVO 2013 Annual Meeting Abstracts
- Page 92 and 93: ARVO 2013 Annual Meeting Abstracts
- Page 94 and 95: ARVO 2013 Annual Meeting Abstracts
- Page 96 and 97: ARVO 2013 Annual Meeting Abstracts
- Page 98 and 99: ARVO 2013 Annual Meeting Abstracts
- Page 100 and 101: ARVO 2013 Annual Meeting Abstracts
- Page 102 and 103: ARVO 2013 Annual Meeting Abstracts
- Page 104 and 105: ARVO 2013 Annual Meeting Abstracts
- Page 106 and 107: ARVO 2013 Annual Meeting Abstracts
- Page 108 and 109: ARVO 2013 Annual Meeting Abstracts
- Page 110 and 111: ARVO 2013 Annual Meeting Abstracts
- Page 112 and 113: ARVO 2013 Annual Meeting Abstracts
- Page 114 and 115: ARVO 2013 Annual Meeting Abstracts
- Page 116 and 117: ARVO 2013 Annual Meeting Abstracts
- Page 118 and 119: ARVO 2013 Annual Meeting Abstracts
- Page 120 and 121: ARVO 2013 Annual Meeting Abstracts
- Page 122 and 123: ARVO 2013 Annual Meeting Abstracts
- Page 124 and 125: ARVO 2013 Annual Meeting Abstracts
- Page 126 and 127:
ARVO 2013 Annual Meeting Abstracts
- Page 128 and 129:
ARVO 2013 Annual Meeting Abstracts
- Page 130 and 131:
ARVO 2013 Annual Meeting Abstracts
- Page 132 and 133:
ARVO 2013 Annual Meeting Abstracts
- Page 134 and 135:
ARVO 2013 Annual Meeting Abstracts
- Page 136 and 137:
ARVO 2013 Annual Meeting Abstracts
- Page 138 and 139:
ARVO 2013 Annual Meeting Abstracts
- Page 140 and 141:
ARVO 2013 Annual Meeting Abstracts
- Page 142 and 143:
ARVO 2013 Annual Meeting Abstracts
- Page 144 and 145:
ARVO 2013 Annual Meeting Abstracts
- Page 146 and 147:
ARVO 2013 Annual Meeting Abstracts
- Page 148 and 149:
ARVO 2013 Annual Meeting Abstracts
- Page 150 and 151:
ARVO 2013 Annual Meeting Abstracts
- Page 152 and 153:
ARVO 2013 Annual Meeting Abstracts
- Page 154 and 155:
ARVO 2013 Annual Meeting Abstracts
- Page 156 and 157:
ARVO 2013 Annual Meeting Abstracts
- Page 158 and 159:
ARVO 2013 Annual Meeting Abstracts
- Page 160 and 161:
ARVO 2013 Annual Meeting Abstracts
- Page 162 and 163:
ARVO 2013 Annual Meeting Abstracts
- Page 164 and 165:
ARVO 2013 Annual Meeting Abstracts
- Page 166 and 167:
ARVO 2013 Annual Meeting Abstracts
- Page 168 and 169:
ARVO 2013 Annual Meeting Abstracts
- Page 170 and 171:
ARVO 2013 Annual Meeting Abstracts
- Page 172 and 173:
ARVO 2013 Annual Meeting Abstracts
- Page 174 and 175:
ARVO 2013 Annual Meeting Abstracts
- Page 176 and 177:
ARVO 2013 Annual Meeting Abstracts
- Page 178 and 179:
ARVO 2013 Annual Meeting Abstracts
- Page 180 and 181:
ARVO 2013 Annual Meeting Abstracts
- Page 182 and 183:
ARVO 2013 Annual Meeting Abstracts
- Page 184 and 185:
ARVO 2013 Annual Meeting Abstracts
- Page 186 and 187:
ARVO 2013 Annual Meeting Abstracts
- Page 188 and 189:
ARVO 2013 Annual Meeting Abstracts
- Page 190 and 191:
ARVO 2013 Annual Meeting Abstracts
- Page 192 and 193:
ARVO 2013 Annual Meeting Abstracts
- Page 194 and 195:
ARVO 2013 Annual Meeting Abstracts
- Page 196 and 197:
ARVO 2013 Annual Meeting Abstracts
- Page 198 and 199:
ARVO 2013 Annual Meeting Abstracts
- Page 200 and 201:
ARVO 2013 Annual Meeting Abstracts
- Page 202 and 203:
ARVO 2013 Annual Meeting Abstracts
- Page 204 and 205:
ARVO 2013 Annual Meeting Abstracts
- Page 206 and 207:
ARVO 2013 Annual Meeting Abstracts
- Page 208 and 209:
ARVO 2013 Annual Meeting Abstracts
- Page 210 and 211:
ARVO 2013 Annual Meeting Abstracts
- Page 212 and 213:
ARVO 2013 Annual Meeting Abstracts
- Page 214 and 215:
ARVO 2013 Annual Meeting Abstracts
- Page 216 and 217:
ARVO 2013 Annual Meeting Abstracts
- Page 218 and 219:
ARVO 2013 Annual Meeting Abstracts
- Page 220 and 221:
ARVO 2013 Annual Meeting Abstracts
- Page 222 and 223:
ARVO 2013 Annual Meeting Abstracts
- Page 224 and 225:
ARVO 2013 Annual Meeting Abstracts
- Page 226 and 227:
ARVO 2013 Annual Meeting Abstracts
- Page 228 and 229:
ARVO 2013 Annual Meeting Abstracts
- Page 230 and 231:
ARVO 2013 Annual Meeting Abstracts
- Page 232 and 233:
ARVO 2013 Annual Meeting Abstracts
- Page 234 and 235:
ARVO 2013 Annual Meeting Abstracts
- Page 236 and 237:
ARVO 2013 Annual Meeting Abstracts
- Page 238 and 239:
ARVO 2013 Annual Meeting Abstracts
- Page 240 and 241:
ARVO 2013 Annual Meeting Abstracts
- Page 242 and 243:
ARVO 2013 Annual Meeting Abstracts
- Page 244 and 245:
ARVO 2013 Annual Meeting Abstracts
- Page 246 and 247:
ARVO 2013 Annual Meeting Abstracts
- Page 248 and 249:
ARVO 2013 Annual Meeting Abstracts
- Page 250 and 251:
ARVO 2013 Annual Meeting Abstracts
- Page 252 and 253:
ARVO 2013 Annual Meeting Abstracts
- Page 254 and 255:
ARVO 2013 Annual Meeting Abstracts
- Page 256 and 257:
ARVO 2013 Annual Meeting Abstracts
- Page 258 and 259:
ARVO 2013 Annual Meeting Abstracts
- Page 260 and 261:
ARVO 2013 Annual Meeting Abstracts
- Page 262 and 263:
ARVO 2013 Annual Meeting Abstracts
- Page 264 and 265:
ARVO 2013 Annual Meeting Abstracts
- Page 266 and 267:
ARVO 2013 Annual Meeting Abstracts
- Page 268 and 269:
ARVO 2013 Annual Meeting Abstracts
- Page 270 and 271:
ARVO 2013 Annual Meeting Abstracts
- Page 272 and 273:
ARVO 2013 Annual Meeting Abstracts
- Page 274 and 275:
ARVO 2013 Annual Meeting Abstracts
- Page 276 and 277:
ARVO 2013 Annual Meeting Abstracts
- Page 278 and 279:
ARVO 2013 Annual Meeting Abstracts
- Page 280 and 281:
ARVO 2013 Annual Meeting Abstracts
- Page 282 and 283:
ARVO 2013 Annual Meeting Abstracts
- Page 284 and 285:
ARVO 2013 Annual Meeting Abstracts
- Page 286 and 287:
ARVO 2013 Annual Meeting Abstracts
- Page 288 and 289:
ARVO 2013 Annual Meeting Abstracts
- Page 290 and 291:
ARVO 2013 Annual Meeting Abstracts
- Page 292 and 293:
ARVO 2013 Annual Meeting Abstracts
- Page 294 and 295:
ARVO 2013 Annual Meeting Abstracts
- Page 296 and 297:
ARVO 2013 Annual Meeting Abstracts
- Page 298 and 299:
ARVO 2013 Annual Meeting Abstracts
- Page 300 and 301:
ARVO 2013 Annual Meeting Abstracts
- Page 302 and 303:
ARVO 2013 Annual Meeting Abstracts
- Page 304 and 305:
ARVO 2013 Annual Meeting Abstracts
- Page 306 and 307:
ARVO 2013 Annual Meeting Abstracts
- Page 308 and 309:
ARVO 2013 Annual Meeting Abstracts
- Page 310 and 311:
ARVO 2013 Annual Meeting Abstracts
- Page 312 and 313:
ARVO 2013 Annual Meeting Abstracts
- Page 314 and 315:
ARVO 2013 Annual Meeting Abstracts
- Page 316 and 317:
ARVO 2013 Annual Meeting Abstracts
- Page 318 and 319:
ARVO 2013 Annual Meeting Abstracts
- Page 320 and 321:
ARVO 2013 Annual Meeting Abstracts
- Page 322 and 323:
ARVO 2013 Annual Meeting Abstracts
- Page 324 and 325:
ARVO 2013 Annual Meeting Abstracts
- Page 326 and 327:
ARVO 2013 Annual Meeting Abstracts
- Page 328 and 329:
ARVO 2013 Annual Meeting Abstracts
- Page 330 and 331:
ARVO 2013 Annual Meeting Abstracts
- Page 332 and 333:
ARVO 2013 Annual Meeting Abstracts
- Page 334 and 335:
ARVO 2013 Annual Meeting Abstracts
- Page 336 and 337:
ARVO 2013 Annual Meeting Abstracts
- Page 338 and 339:
ARVO 2013 Annual Meeting Abstracts
- Page 340 and 341:
ARVO 2013 Annual Meeting Abstracts
- Page 342 and 343:
ARVO 2013 Annual Meeting Abstracts
- Page 344 and 345:
ARVO 2013 Annual Meeting Abstracts
- Page 346 and 347:
ARVO 2013 Annual Meeting Abstracts
- Page 348 and 349:
ARVO 2013 Annual Meeting Abstracts
- Page 350 and 351:
ARVO 2013 Annual Meeting Abstracts
- Page 352 and 353:
ARVO 2013 Annual Meeting Abstracts
- Page 354 and 355:
ARVO 2013 Annual Meeting Abstracts
- Page 356 and 357:
ARVO 2013 Annual Meeting Abstracts
- Page 358 and 359:
ARVO 2013 Annual Meeting Abstracts
- Page 360 and 361:
ARVO 2013 Annual Meeting Abstracts
- Page 362 and 363:
ARVO 2013 Annual Meeting Abstracts
- Page 364 and 365:
ARVO 2013 Annual Meeting Abstracts
- Page 366 and 367:
ARVO 2013 Annual Meeting Abstracts
- Page 368 and 369:
ARVO 2013 Annual Meeting Abstracts
- Page 370 and 371:
ARVO 2013 Annual Meeting Abstracts
- Page 372 and 373:
ARVO 2013 Annual Meeting Abstracts
- Page 374 and 375:
ARVO 2013 Annual Meeting Abstracts
- Page 376 and 377:
ARVO 2013 Annual Meeting Abstracts
- Page 378 and 379:
ARVO 2013 Annual Meeting Abstracts
- Page 380 and 381:
ARVO 2013 Annual Meeting Abstracts
- Page 382 and 383:
ARVO 2013 Annual Meeting Abstracts